Clinical trial
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or…
NCT00474188 · Celgene Corporation, Industry · Terminated
Key facts
| NCT number | NCT00474188 |
|---|---|
| Title | A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| Official title | A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid ®) in Combination With Dexamethasone in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diffuse Large B-cell Lymphoma |
| Intervention type | Drug |
| Interventions | CC-5013 (lenalidomide), dexamethasone |
| Enrollment | 26 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | May 16, 2007 |
| Last update posted | Sep 2, 2009 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: